Baudax Bio, Inc.
BXRX 0.00 Stock Price Baudax Bio, Inc.

Home
  /  
Stock List  /  Baudax Bio, Inc.
Range:0.0137-3.4699Vol Avg:424847Last Div:0Changes:0.19
Beta:1.58Cap:0.00BCurrency:USDExchange:NASDAQ
Sector:HealthcareIPO:Thu Nov 14 2019Empoloyees:9
CUSIP:07160F206CIK:0001780097ISIN:US07160F4046Country:US
CEO:Dr. Geraldine A. Henwood Ph.D.Website:https://www.baudaxbio.com
Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with non-NSAID analgesics. Its products under development includes BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMBA, which is in phase I clinical trial; BX3000, an NMBA reversal agent; and Dex-IN, a proprietary intranasal formulation of dexmedetomidine. The company was incorporated in 2019 and is based in Malvern, Pennsylvania.

Stock Details

The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
DMCA.com Protection StatusPowered by StackThrow